HK Stock Market Move | MEDBOT-B(02252) continues to rise by over 7%, National Medical Insurance Administration clarifies Siasun Robot & Automation surgical fee guidelines for the first time.

MEDBOT-B (02252) rose over 7%, as of the time of writing, it has risen 7.21%, reaching HK$28.26, with a trading volume of HK$72.65 million. On the news front, the National Healthcare Security Administration recently issued the "Guidelines for Pricing of Surgical and Therapeutic Assistance Medical Services (Trial)", focusing on advanced medical technologies such as 3D printing, surgical Siasun Robot&Automation, and remote surgery. They have standardized 37 price items, 5 additional items, and 1 extension item, aiming to lead the upgrade of medical technology through pricing mechanisms and promote the transition from "traditional treatment" to "precision medicine". It is worth noting that previous announcements by Minimally Invasive Siasun Robot&Automation have shown that, based on preliminary internal statistics within the group, the overall order volume of the group's core products in the endoscopy, orthopedics, and vascular intervention fields has exceeded 230 units. Among them, the core product, the Minimally Invasive Siasun Robot&Automation (Minimally Invasive) surgical system, has accumulated more than 160 commercial orders worldwide, including nearly 120 new orders this year. According to publicly available data, by 2025, Minimally Invasive's global order volume has ranked among the top two globally.